News

The Company previously completed a seed round fundraising in 2008 concurrent with its founding. The Series A round was led by the Redmile Group and joined by Janus

ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the C9ORF72 gene that involves hundreds of additional repetitions of a six base

Promacta can now be used in combination with standard immunosuppressive therapy to treat the rare blood disorder. SAA is a condition in which the bone marrow of the

CX-01 is an investigational agent that has the potential to enhance the effectiveness of leukemia treatments by disrupting the adhesion of leukemia cells in the protective bone marrow

Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets. Viamet Pharmaceuticals

The companies have announced a development strategy for M710, a proposed biosimilar to Eylea injection. Eylea is a vascular endothelial growth factor (VEGF) inhibitor developed to treat neovascular

The job cuts will affect employees engaged in the company's commercial and other functions. Allergan said in a US Securities and Exchange Commission filing that it will also terminate nearly 400 open

CNTX-4975 is a non-opioid therapy, which is designed to inject directly into the painful joint. The company has secured funding in the series D financing round led by New

With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. PEAR is the